Calton & Associates, Inc. Cellectis S.A. Transaction History
Calton & Associates, Inc.
- $204 Million
- Q1 2024
A detailed history of Calton & Associates, Inc. transactions in Cellectis S.A. stock. As of the latest transaction made, Calton & Associates, Inc. holds 20 shares of CLLS stock, worth $38. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20Holding current value
$38% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding CLLS
# of Institutions
31Shares Held
9.83MCall Options Held
0Put Options Held
30.9K-
Long Focus Capital Management, LLC San Juan, PR4.49MShares$8.53 Million0.64% of portfolio
-
Capital International Investors Los Angeles, CA1.85MShares$3.51 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$2.73 Million0.0% of portfolio
-
Baillie Gifford & CO827KShares$1.57 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA425KShares$806,6120.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $86.5M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...